KR20120017152A - Hydrocolloid containing active ingredient - Google Patents

Abstract

PURPOSE: A hydrocolloid formulation containing an active drug is provided to be applied onto skin and to enhance wound healing effect. CONSTITUTION: A hydrocolloid formulation contains 2-15 wt% of super disintegrant. The formulation further contains an active drug which is able to heal wounds. The super distintegrant is alginic acid, alginates, calcium carboxy methyl cellulose, chitosan, cross povidone, or sodium starch glycolate. The active drug is fusidic acid, pharmaceutically acceptable salt thereof, Centella asiatica, or benzalkonium chloride.

Description

Hydrocolloid containing active drug

The present invention relates to a hydrocolloid formulation for containing an active drug which can be expected to have a wound healing efficacy.

The ideal dressing formulation should be formulated to maintain the moist environment of the wound, adequate absorbency and moisture permeability, to prevent drying of the wound surface and to prevent swelling of the surrounding normal skin. In addition, the ideal dressing formulation should be functional, such as protecting the wound from outside and preventing bacterial invasion, and should not stick to the wound surface and cause damage to new tissue, etc., and should be non-irritating.

Hydrocolloid preparations are one of the dressing agents used for the purpose of wound protection and skin regeneration in mild burns, acute and chronic wounds, more than other dressing agents hydrogels, foams and films. It is widely used. Representative commercially available hydrocolloidal formulations include ConvaTec's Aquacel ™, Colorlast's Comfeel ™ and 3M's Tegasorb.

Hydrocolloid formulations have the advantage of promoting epithelialization of wounds by providing a humid environment in the form of gels by reacting with exudates when wounds are attached. In addition, the storage stability is higher than the hydrogel formulation, and has a self-adhesive strength, unlike other formulations has the advantage that does not require a secondary dressing agent.

Hydrocolloid preparations that improve wound healing ability than conventional dressing preparations are composed of hydrophilic polymers that have hydrophilic functional groups and absorb water but do not dissolve in water and hydrophobic polymers that give elasticity while giving adhesion to skin. It has a three-dimensional network to function properly.

Korean Patent No. 0299916 discloses carboxymethylcellulose, cellulose, alginic acid, agar, pectin, gelatin, styrene-ethylene-butadiene-styrene copolymer, isobutylene rubber, and isoprene rubber as polymers of hydrocolloid preparations. However, the hydrocolloid preparation, which is composed only of a polymer as described above, shows an effect of treating wounds by absorbing exudate to provide an appropriate wetting environment, but it is already infected or concerned about infection because it does not contain an active drug that can be expected to treat the wound. There is no direct wound healing effect from the wound.

In order to anticipate the effects of direct wound healing, there is a method of directly administering active drugs such as antibiotics, disinfectants, wound healing agents, orally or transdermally. Among the active drugs having typical wound healing effects, antibiotics include fusidic acid or a pharmaceutically acceptable salt thereof, mupirosine, neomycin, bacitracin, gentamycin, lincomycin, and erythromycin. Benzalkonium, Bentrinium Chloride, Acrinol, Triclosan, Triclocarban and Cetylpyridinium Chloride and Donepin Bromide, etc.Wound treatment agents include Centella asiatica, Heparin, Sephax and X-Allantoin, Fibroblast growth factor ( Granulation promoters such as FGF), hepatic fibroblast growth factor (HGF), and marker cell proliferation factor (EGF) are known and applied to various wounds.

Such antibiotics, disinfectants, wound treatments, and the like are often administered as external preparations such as ointments, but these external preparations have some effects in promoting wound healing, but they are accompanied by pain when applied to the wound or applied to the skin. Pollutants may penetrate into the wound site from the outside, stickiness remains after application, resulting in discomfort in activity, and the wound site and the drug administration site are exposed and thus unsafe.

Polyurethane foam dressing formulations containing active drugs have been introduced for use in wounds that are infected or are susceptible to infection as well as to create a moist environment that facilitates wound healing. The Republic of Korea Patent No. 0404140 is a polyurethane foam prepared by mixing and stirring a polyurethane prepolymer having an isocyanate end with a crosslinking agent, a blowing agent, an antimicrobial agent and an additive, and then injecting into a mold to foam. A dressing formulation is described. In addition, Korean Patent No. 0080823 describes a hydrogel preparation containing water, a hydrophilic polymer and a polyol including an active drug.

Conventional hydrocolloid preparations are known to have only a function of absorbing water in the wound area, and research on the function of releasing a substance inside the colloid has been insignificant. However, US Pat. No. 5,745,633 describes various drugs such as antibiotics and disinfectants. Hydrocolloid formulations that contain and are released into the percutaneous body are introduced.

However, conventional polyurethane foam formulations, hydrogel formulations, and hydrocolloid formulations containing active drugs have common problems. The drug can be manifested when the active drug inside the formulation is released out and touches the wound surface, because the release of the drug may vary depending on the amount of exudate. In other words, the drug is released due to the swelling of the preparation by a large amount of exudate at the beginning with a large amount of exudate, but the amount of the exudate is small, and the release of the drug is not well at a later stage. Therefore, whether the drug is released and the amount of release is greatly influenced by the amount of exudate, and thus the release pattern may be unstable and the difference between the wounds may be large. In addition, the hydrocolloid formulation has a hydrophobic polymer as a component and has a problem of adhesion and elasticity of the skin, but drug release is extremely limited.

Therefore, there has been a need for the development of a dressing formulation that minimizes the difference in drug release due to exudates of such wounds, thereby creating a moist environment regardless of the amount of exudates and enabling drug release continuously.

In the present invention, even if the active drug is contained in the hydrocolloid formulation, the active drug-containing hydro which can have a direct wound healing effect at the same time as the exudation is continuously released and the active drug is released, regardless of the amount of exudate when applied to the wound. It is an object to provide a colloidal preparation.

The present invention relates to a hydrocolloid formulation containing an active drug and a superdisintegrant.

In order to solve the problems shown in the prior art, the hydrocolloid preparation containing the active drug should be designed to satisfy the following conditions.

First, they must be prepared to retain the basic physical properties of conventional hydrocolloid formulations, even if they contain active drugs.

Second, there must be a sustained release of the drug through sufficient absorption for effective application of the drug in the wound.

Third, even if it contains an active drug, the collapse of the structure due to the absorption of the exudate of the hydrocolloid formulation should not appear.

The present invention shows the sustained release of the drug through sufficient absorption in the wound, while maintaining the basic physical properties of the conventional hydrocolloid formulation, and can be expected to treat the efficacy of wound treatment by containing the active drug without the collapse of the structure due to the absorption of exudate As a hydrocolloid formulation, a hydrocolloid formulation containing a superdisintegrant is provided.

The active drug according to the present invention is a drug that can be expected to be effective in wound healing, including antibiotics, antiseptics, wound healing agents, such as fusidic acid, centella asiatica, mupyrosine, neomycin, bacitracin, gentamicin, Lincomycin, Erythromycin, Heparin, Benzalkonium Chloride, Bentrinium Chloride, Acrinol, Triclosan, Triclocarban, Cetylpyridinium Chloride, Donepine Bromide, Cefaziox and Allantoin, Fibroblast Proliferation Factor (FGF), Liver Fiber It may be selected from the group consisting of granulation promoters such as proliferation factor (HGF), marker cell proliferation factor (EGF) and the like. Preferably, it is fusidic acid or a pharmaceutically acceptable salt thereof, centella asiatica, benzalkonium chloride. And acrilin, triclosan, and the active drug is present in a dispersed form in the hydrophilic polymer of the hydrocolloid preparation.

The superdisintegrant, which is a feature of the present invention, serves to reduce the release difference according to the amount of the exudate, and in particular, serves to increase the absorption of the exudate as a hydrocolloid formulation to favor a wet environment composition. Super disintegrants include alginates such as alginic acid and calcium alginate, calcium carboxymethylcellulose, chitosan, sodium croscarmellose, crospovidone, low-substituted hydroxypropyl cellulose, methylcellulose, gelatinized starch, sodium starch glycolate (sodium starch glycolate) may be 1 or 2 or more selected from the group consisting of, but is not limited thereto. Preferably it is 1 or 2 or more selected from the group consisting of sodium croscarmellose, crospovidone, sodium starch glycolate.

In the present invention, the super disintegrant is contained in an amount of 2 to 15% by weight relative to the total weight of the hydrocolloid preparation, and when the super disintegrant is added in an amount of 1 wt% or less, there is no effect of improving the absorption and drug release ability according to the use of the super disintegrant. If more than 16% by weight is added, it may be difficult to maintain the form of the formulation due to excessive absorption of exudate.

In the present invention, the hydrophilic polymer is generally contained in a known weight percent of the hydrocolloid formulation, that is, 10 to 50 weight percent of the total hydrocolloid formulation weight.

The hydrophilic polymer according to the present invention absorbs the wound site exudate and plays a role in creating a moist environment, polyacrylic acid, polyvinylpyrrolidone, hydroxyalkyl cellulose, carbomer, polyvinyl alcohol, chitosan, kinin, alginates , Carboxymethylcellulose, polyhexamethylene biguanide, carrageenan, polyethylene oxide, polysaccharide, collagen, gelatin, hyaluronic acid, xanthan gum, acacia rubber, guar rubber, arginic acid, agar, gelatin, gum arabic, traga Gant, karaya gum, pectin, dextran and starch, or salts thereof may be one or two or more selected from the group consisting of, but not limited to. Preferably alginates or sodium carboxymethylcellulose can be selected.

The present invention also encompasses hydrophobic polymers used in general hydrocolloid formulations. The hydrophobic polymer serves as a pressure-sensitive adhesive of the hydrocolloid formulation, and may be selected from one or two or more from the group consisting of a pressure-sensitive adhesive material, a thermoplastic elastomer, a tackifier, and the like.

Suitable pressure sensitive adhesive materials include one or two or more selected from the group consisting of various natural or synthetic viscous or elastomeric materials such as natural rubber, silicone rubber, acrylonitrile rubber, polyurethane rubber, polyisobutylene, polyisoprene, and the like. It is not limited thereto. Preferably polyisoprene and polyisobutylene may be selected. Thermoplastic elastomers include polyisoprene, polyisobutylene, isobutylene rubber, polyethylene-propylene rubber, polyethylene-propylene diene-modified rubber, styrene-butadiene-styrene, styrene-isoprene-styrene, styrene-ethylene-propylene-styrene and styrene It may be one or two or more selected from the group consisting of -ethylene-butylene-styrene copolymer polymer, but is not limited thereto. Preferably styrene-butadiene-styrene and styrene-isoprene-styrene may be selected. In addition, the tackifier according to the present invention is a thermoplastic material having a molecular weight in the range of 300 ~ 3000, petroleum resin based aliphatic C5, aromatic C9, C5 / C9, and hydrogenated DCPD (Dicyclopentadiene) resin is mainly used, preferably hydrogenated DCPD Resin can be selected.

In addition, the hydrocolloid formulations according to the present invention may further include oils, antioxidants and the like generally used in hydrocolloid formulations. The oil plays a role in imparting flexibility and processability in the hydrocolloid matrix. Paraffinic oils and naphthenic oils are mainly used, preferably paraffinic oils may be selected. Antioxidants play a role in preventing adhesive oxidation at high temperatures.Butylated hydroxytoluene (BHT), Vulkanox BKF, Lanxess, Irganox 1076, 1010, 565 (Irganox 1076, 1010, 565), Ciba Specialty Chemicals, and the like.

In the hydrocolloid preparation according to the present invention, a hydrophobic polymer, an oil, an antioxidant, and the like are uniformly mixed at a high temperature in a stirrer to prepare a rubbery elastomer matrix. The hydrophilic polymers may be mixed and uniformly mixed.

The hydrocolloid formulation of the present invention contains a super-disintegrant, even when the hydrocolloid formulation containing the active drug is prepared, when applied to the skin, it absorbs the exudates of the applied area to create a moist environment and irrespective of the amount of the exudate. By continually releasing the active drug, it has a direct and elevated therapeutic effect on wounds and the like.

1 compares the release aspects of Examples 26, 28-30, and Comparative Examples 13 and 15.
2 compares the release aspects of Examples 23-27 and Comparative Examples 10-14.
Figure 3 shows the wound recovery evaluation results between Example 21 and the commercial formulation
4 shows the results of evaluation of wound recovery between Example 26 and a commercial formulation.

Hereinafter, the present invention will be described in detail by Examples and Experimental Examples. However, the following Examples and Experimental Examples are only for illustrating the present invention, and the scope of the present invention is not limited by the Examples and Experimental Examples.

< Example  1> Super disintegrant  contain Hydrocolloid  Manufacture of pharmaceutical preparations

The styrene-isoprene-styrene copolymer was stirred and dissolved in a vessel heated to 180 to 200 ° C, and then irganox was added and stirred. After the temperature was lowered and stirred with polyisobutylene rubber, petroleum resin, and paraffin oil at 140 to 160 ° C., sodium carboxymethyl cellulose and super disintegrating croscarmellose sodium were stirred at 100 to 120 ° C., and then hot It was put in a melt coater and laminated to a constant thickness on a secondary paper. After drying at room temperature, it was laminated with a polyurethane film to prepare a general hydrocolloid formulation.

< Example  2 to 12 Super disintegrant  contain Hydrocolloid  Manufacture of pharmaceutical preparations

A superdisintegrant-containing hydrocolloid preparation was prepared in the same manner as in Example 1 using the compositions shown in Table 1 below, and Examples 2 to 12 were prepared. The superdisintegrant during the preparation was put together with the hydrophilic polymer and stirred.

< Example  13 to 30> Active drugs and Super disintegrant  contain Hydrocolloid  Manufacture of pharmaceutical preparations

A hydrocolloid formulation was prepared in the same manner as in Example 1, using the composition shown in Table 2 below, and the active drug was added together with a hydrophilic polymer and a superdisintegrant and stirred during the preparation process. The compositions shown in Table 2 were each prepared to obtain Examples 13 to 30.

< Comparative example  1 to 9> Super disintegrant  contain Hydrocolloid  Manufacture of pharmaceutical preparations

In the same manner as in Example 1, a superdisintegrant-containing hydrocolloid formulation was prepared using the composition shown in Table 3 below, and Comparative Examples 1 to 9 were prepared.

< Comparative example  10 to 14 Contains only active drug Hydrocolloid  Manufacture of pharmaceutical preparations

In the same manner as in Example 1, a hydrocolloid formulation containing only an active drug without a superdisintegrant was prepared using the composition shown in Table 4 below, and Comparative Examples 10 to 14 were prepared. The active drug was mixed with the hydrophilic polymer during the preparation and stirred.

< Comparative example  15 to 17 Active drugs and Super disintegrant  contain Hydrocolloid  Manufacture of pharmaceutical preparations

A hydrocolloid formulation was prepared in the same manner as in Example 1, using the composition shown in Table 5 below, and the active drug was added together with the hydrophilic polymer and the superdisintegrant and stirred during the preparation. Each of the compositions shown in Table 5 was prepared to obtain Comparative Examples 15 to 17.

< Experimental Example  1> Physical property evaluation

This experiment is an experiment to determine whether the super-disintegrant-containing hydrocolloid preparation and the hydrocolloid preparation containing the active drug and the super-disintegrator according to the present invention maintain the physical properties of the adhesive force of the conventional hydrocolloid preparation.

Examples 1 to 12, which are the superdisintegrant-containing hydrocolloid preparations according to the present invention, Examples 13 to 30, which are the active drug and the super-disintegrant-containing hydrocolloid preparations, and Comparative Example 1, which are the super-disintegrant-containing hydrocolloid preparations 9 to 9, Comparative Examples 10 to 13, which is a hydrocolloid formulation containing only an active drug without superdisintegrant, and a comparative example of an active drug and a superdisintegrant-containing hydrocolloid formulation having different contents of the superdisintegrant. Physical property evaluations were carried out including 14-17 and two commercially available representative hydrocolloid formulations. Physical property evaluation of hydrocolloid formulations was evaluated by Peel adhesion, Tack and Young`s modulus commonly used in the art.

Peel adhesion evaluation was performed by using adhesive-release 1000 tester (cheminstrument) to attach the specimen to a stainless plate with a constant force using a roller and at a fixed speed (300 mm / min) at a 180 ° incline. The average value of the force of falling was measured.

Tack evaluation measured the force of the probe blowing on the specimen using a probe stack (cheminstrument).

Young`s modulus evaluation was measured by Texture Analyzer (Micro systems) by fixing the hydrocolloid preparation to the probe and applying a constant force.

E = Tensile strength / Elongation at break

As can be seen in Table 6, Examples 1 to 12 of the super disintegrant-containing hydrocolloid formulation according to the present invention, Examples 13 to 30 of the super-disintegrant and active drug-containing hydrocolloid formulation It exhibited physical properties with adhesive strength equivalent to that of commercial hydrocolloid formulations.

In the above experimental results, even if the super-disintegrating agent and the drug in the hydrocolloid formulation in the present invention can be confirmed that the basic physical properties of the hydrophobic polymer is not significantly changed.

< Experimental Example  2> Skin irritation evaluation

This experiment is to test the skin irritation evaluation to determine whether the active drug and the super-disintegrant-containing hydrocolloid preparation according to the present invention has a safety problem, unlike the conventional hydrocolloid preparation.

Examples 13 to 30, which are the active drug and the superdisintegrant-containing hydrocolloid preparation according to the present invention, and Comparative Examples 10 to 13, which are the hydrocolloid preparations containing only the active drug and do not contain the superdisintegrant, are superdisintegrants The safety was evaluated including Comparative Examples 14 to 17, which are the active drug having different contents of and the hydrocolloid preparations containing the superdisintegrant, and two representative hydrocolloid formulations commercially available. Safety evaluation was evaluated through the skin irritation commonly used in the art and the results are shown in Table 8.

As a test animal, using New Zealand White Rabbit 2-3 kg, the preparation was attached to rabbit skin for 2 hours by 2 cm x 2 cm and removed for 1 hour, 24 hours, 48 hours, and 72 hours. Observation was made according to the evaluation table. The experimental animals secured the test area by shortly cutting both sides of the spine the day before. The test area was cleaned with alcohol.

As can be seen in Table 8, Examples 13 to 30 of the super disintegrant and the active drug-containing hydrocolloid preparation according to the present invention do not affect the skin irritation as a result of skin irritation evaluation similar to commercially available hydrocolloid preparations. You can check.

In the above experimental results, it can be seen that the formulation can ensure the safety even when formulated by containing a drug and a super disintegrant in a hydrocolloid formulation in the present invention.

< Experimental Example  3> Superdisintegrant  Evaluation of Absorption Rate According to Difference in Content

This experiment is an experiment to evaluate the effect of the exudates according to the degree of super disintegrant in the hydrocolloid formulation.

Examples 1 to 30 of the super disintegrant-containing hydrocolloid preparation according to the present invention, Comparative Examples 10 to 13 of the hydrocolloid preparation containing no super-disintegrant, hydro-containing different amounts of the present invention and super disintegrant Absorption rate evaluation was performed including the colloidal formulations Comparative Examples 1-9, Comparative Examples 14-17, and two typical hydrocolloid formulations commercially available. Absorption rate evaluation is shown in Table 9 evaluated by the swelling test commonly used in the art.

The dried hydrocolloid preparation was taken in a size of 2 cm x 2 cm and immersed in 37 ° C. PBS (Phosphate Buffered saline) for 24 hours, and then weighed (We). Measured. Finally, the following equation was used.

% Absorption = (We / Wo) x 100

As can be seen in Table 9, Examples 1 to 30 according to the present invention containing a super disintegrant showed a very excellent absorption capacity than Comparative Examples 10 to 14 and commercially available agents do not contain a super disintegrant.

And, even in the case of containing a super disintegrant, as in Comparative Examples 2, 3, 5, 6, 8, 9, 16, 17, in the hydrocolloid formulation containing more than 15% by weight of the superdisintegrant, Absorption rate could not be measured because it was difficult to maintain the shape.

In addition, the hydrocolloid preparations of Comparative Examples 1, 4, and 7 containing 1 wt% or less of the superdisintegrant exhibited similar absorption to commercially available formulations without using the superdisintegrant, and improved absorption by using the superdisintegrant. It can be confirmed that it is not supported.

In the above test results, when using 15% by weight or less of the super disintegrant in the hydrocolloid formulation was able to obtain a very good absorption rate than the commercially available products, except that containing 1% or less by weight of the super disintegrant is of a similar degree to the commercial product It can be seen that the absorption rate.

Therefore, when the ratio of adding the superdisintegrant in the present invention is 2 to 15% by weight relative to the total weight of the hydrocolloid formulation, it is determined that it can serve as an accelerator of excellent drug release in the formulation.

Therefore, the hydrocolloid formulations according to the present invention exhibit excellent absorption and thus are preferable formulations for the construction of a wet environment for wound healing, and it is believed that the hydrocolloid formulations will favorably release the drug regardless of the amount of exudate.

< Experimental Example  4> Superdisintegrant  Evaluation of drug release according to the difference in content

This experiment is to evaluate the drug release change of the hydrocolloid preparation according to the difference in the content of super disintegrant.

Examples 23 to 30, which is a hydrocolloid preparation containing a superdisintegrant and a drug according to the present invention, Comparative Examples 10 to 14, which is a hydrocolloid preparation containing only an active drug, and 1% by weight of an active drug and a superdisintegrant The drug release characteristics of Comparative Example 15, a hydrocolloid formulation, were compared and evaluated. Comparative examples containing more than the content of the super disintegrant according to the present invention in the absorption rate evaluation according to the difference in the content of the super disintegrant is difficult to maintain the form of the formulation according to the absorption of exudates, so the absorption rate could not be measured in this experiment Excluded.

The hydrocolloid preparation containing the active drug was subjected to a drug release test while maintaining the conditions of 37 ± 1 ° C. and 30 RPM using an up-down dialless tester (Dialysis tester, Lab.fine). Each specimen was sampled at 500 μl using a microsyringe at regular intervals, and the same temperature was added to the same solution after sampling to maintain the sink condition. The concentration of the sample taken was detected using HPLC and shown in FIG. 1 and FIG. 2 as the release amount (%) relative to the total amount contained in the hydrocolloid formulation.

As can be seen in Figure 1, the hydrocolloid formulations of Examples 26, 28 to 30 containing 2 to 15% by weight of the superdisintegrant according to the present invention showed a very good drug release.

In contrast, the hydrocolloid preparation of Comparative Example 13 containing no superdisintegrant shows a low drug release pattern, and the hydrocolloid preparation containing only the active drug without the superdisintegrant is important for initial wound release and wetting. It can be seen that it is not preferable as a formulation that does not occur simultaneously with environmental composition.

And unlike the present invention, it was confirmed that the hydrocolloid preparation of Comparative Example 15 containing 1 wt% of a superdisintegrant did not show a drug release promoting effect as in the present invention. It is believed that this is because the drug-containing hydrocolloid formulation is poor in absorbency and thus is difficult to release the drug in the hydrophobic polymer.

As shown in Figure 2, the hydrocolloid formulations of Examples 23 to 27 according to the present invention are all formulations containing a high concentration of active drug at a low concentration despite the superdisintegrant 2% by weight relative to the total weight It can be seen that the super-disintegrating agent in the hydrocolloid formulation contains 2% by weight relative to the total weight of the drug and thus serves as an advantageous release accelerator for releasing the drug.

On the contrary, it can be seen that the hydrocolloid preparations of Comparative Examples 10 to 14, which do not contain the superdisintegrant, are not preferable as preparations that do not simultaneously occur in initial drug release and wet environment composition in wound healing.

Therefore, as in the present invention, the hydrocolloid preparation containing 2 to 15% by weight of the superdisintegrant is excellent in the release pattern of the active drug and is continuously active simultaneously with the exudate absorption regardless of the amount of exudate when applied to the wound. It is thought that the drug can be released and have a direct wound healing effect while creating a moist environment.

It is also contemplated that the present invention can produce controlled release formulations by controlling the initial drug release according to the amount of superdisintegrant.

< Experimental Example  5> Wound recovery assessment

Wound recovery evaluation was performed as follows for Examples 21 and 26 and the commercially available Duoderm EXTRA THIN ™ (ConvaTec) according to the present invention.

The mean age was 6-8 weeks, and the weight was 250-300g SD rats. The breeding environment was reared in the general breeding room (temperature 23 ± 2 ° C, humidity 55-60%, lighting from 7 am to 7 pm) until the end of the experiment, and the feed was supplied with general feed, and the water was fed with normal tap water. Used. Wound induction is anesthetized with ketamine & xylazine in rats without any abnormality during the acclimation period, followed by epilation and disinfection of the skin. A wound of mm × 15 mm was caused. After the dressing was performed, the area was measured using grid paper according to time, and the wound size was obtained. The recovery rate was evaluated by visual evaluation and the wound healing effect was measured in FIG. 3 and FIG. 4.

Wound Recovery Rate = (First scratch size-Late size) / First scratch size * 100

As can be seen in Figures 3 and 4, the formulations of Examples 21 and 26, which are hydrocolloid formulations containing the superdisintegrant and active drug according to the present invention, showed very good effect of wound recovery.

On the contrary, the commercial preparations showed the effect of wound healing rather than no treatment, but showed much lower wound healing effect than the embodiment according to the present invention. It is believed that this is because the drug-containing hydrocolloid formulation has a superior absorption rate than the commercially available formulation and a composition containing the drug.

In the above experimental results, by preparing a super disintegrant as containing a drug in the hydrocolloid formulation as in the present invention, regardless of the amount of exudate at the wound site, the direct treatment effect according to the release of the drug and wetting for natural wound healing It is believed that the formulation that can create an environment will exhibit a better wound healing effect than the conventional hydrocolloid formulation.

Claims (6)

A hydrocolloid formulation characterized by containing 2 to 15% by weight of superdisintegrant relative to the total weight of the hydrocolloid formulation.
The hydrocolloid formulation of claim 1, which further contains an active drug that can be expected to treat the wound.
2. The superdisintegrant according to claim 1, wherein the superdisintegrant is alginic acid, alginates, calcium carboxymethylcellulose, chitosan, sodium croscarmellose, crospovidone, low substituted hydroxypropyl cellulose, methylcellulose, gelatinized starch and sodium starch glycolate ( sodium starch glycolate).
4. The hydrocolloid formulation of claim 3, wherein the superdisintegrant is selected from sodium croscarmellose, crospovidone, and sodium starch glycolate.
The active drug according to claim 2, wherein the active drug is fusidic acid or a pharmaceutically acceptable salt thereof, centella asiatica, mupyrosine, neomycin, bacitracin, gentamycin, lincomycin, erythromycin, heparin, benzalkonium chloride. , Bentrinium Chloride, Acrinol, Triclosan, Triclocarban, Cetylpyridinium Chloride, Donepyne Bromide, Cefazonex, Allantoin, Fibroblast Propagation Factor (FGF), Hepatic Fibrosis Proliferation Factor (HGF) and Marker Cell Proliferation Factor ( EGF) is selected from hydrocolloid formulations.
6. The hydrocolloid formulation of claim 5, wherein the active drug is selected from fusidic acid or a pharmaceutically acceptable salt thereof, centella asiatica, and benzalkonium chloride.

Images